Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index; 11 of the 90 sources its claims cite were checked for support.
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label. In this review, we discuss some controversial diagnostic and therapeutic aspects of PCOS, such as the role of insulin resistance, inflammation, and hyperandrogenism. We also evaluated the advantages and disadvantages of contraceptive therapy and antiandrogens.
Overview
CoChat Summary
TL;DR
This review discusses controversies in the pathogenesis, diagnosis, and treatment of polycystic ovary syndrome (PCOS), focusing on insulin resistance, inflammation, and hyperandrogenism. It argues that therapy must be individualized and that, apart from combined oral contraceptives (COCs), most drugs used for PCOS remain off-label, with larger and longer-term studies needed.
Key findings
- PCOS prevalence varies by diagnostic criteria: 4–8% by NIH/NICHD criteria and approximately 18% by Rotterdam criteria; the Rotterdam criteria are endorsed by a recent international evidence-based guideline.
- Insulin resistance is common in PCOS, worsened by hyperandrogenism-related adipose tissue accumulation, and compensatory hyperinsulinemia stimulates ovarian theca androgen production and decreases hepatic SHBG synthesis, increasing total and free androgens.
- Chronic low-grade inflammation is associated with increased white blood cell count, CRP, IL-6, IL-18, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1; aldosterone and the aldosterone/renin ratio are often increased in PCOS and may accentuate inflammation and metabolic/cardiovascular disorders.
- Treatment should start with lifestyle improvement; metformin, inositols (with a MYO:DCI ratio of 40:1 described as most effective), GLP-1 receptor agonists, and SGLT2 inhibitors are discussed, while COCs and antiandrogens have benefits and risks; spironolactone is preferred among antiandrogens because it also has anti-inflammatory action.
Methods
- Narrative review of published literature on PCOS pathogenesis, diagnosis, and treatment, with emphasis on insulin resistance, inflammation, and hyperandrogenism.
- The paper synthesizes prior studies and guidelines, including diagnostic criteria, PCOS phenotypes A–D, androgen measurement issues, insulin resistance assessment, and therapeutic options.
- No primary data collection, new patient sample, or systematic meta-analysis is described.
Limitations
- Stated: many PCOS drugs are off-label; more randomized controlled trials and long-term studies are needed; larger samples are needed to evaluate new therapies and inflammation in adipose tissue; microbiome role requires further study; studies of third-generation contraceptives are short-term, discordant, and often limited in patient numbers.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or new empirical data, so conclusions rely on interpretation of cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 7 Not valid · 66 Not checked · 16 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The administration of drugs with anti-androgenic activity improves insulin resistance [26].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 4. The Pathogenetic Role of Hyperandrogenism in PCOS
What the sources say
- Disputedcites [26] Armanini, 2016, Spironolactone in the treatment of polycystic ovary syndrome, Expert Opin. Pharmacother. sourceExperimental — accuracy not yet measured
Section 3 (page unavailable) discusses hormonal contraceptives containing progestins with antiandrogenic activity, but says the available data do not demonstrate a positive or negative effect on insulin resistance. The paper discusses spironolactone’s benefits for androgen-related symptoms; it does not establish the claimed improvement in insulin resistance. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“insulin resistance, a very common condition in PCOS, which is worsened by hyperandrogenism-related adipose tissue accumulation [3] and is involved in both the pathogenesis and the progression of the disease [4].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 1. Introduction
What the sources say
- Supportedcites [3] Dumesic, 2020, Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective, Curr. Opin. Endocr. Metab. Res. source
The Insulin resistance section states that 60–95% of women with PCOS have insulin resistance, supporting the description of it as very common. (LLM, conf=0.95)
- Not checked yetcites [4] Dunaif, 2012, Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications, Endocr. Rev. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another important pro-inflammatory agent involved in the pathogenesis of PCOS is adipose tissue [18].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 3. The Pathogenetic Role of Inflammation in PCOS
What the sources say
- Partly supportedcites [18] Makki, 2013, Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines, ISRN Inflamm. sourceExperimental — accuracy not yet measured
Our copy supports the general half of the claim: Section 1 states that obesity is a proinflammatory condition and that 'white adipose tissue (WAT) is the key site mediating systemic inflammation,' and Section 1.1 that obese adipose tissue mainly releases proinflammatory cytokines (TNF-α, IL-6, leptin, resistin...) contributing to insulin resistance. PCOS appears only once, in Section 1, where 'polycystic ovarian diseases' is listed among metabolic diseases for which excess adiposity is an established risk factor (citing ref [1]) — a risk-factor statement, not a pathogenic mechanism. The source nowhere attributes to adipose tissue a pro-inflammatory role in the pathogenesis of PCOS specifically; its scope is obesity-induced inflammation and insulin resistance/T2D (Section 3, Concluding Remarks). The PCOS-specific causal/pathogenic part of the citing sentence is unsupported by this source. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ideally, a progestin with the lowest possible androgenic action such as cyproterone acetate, chlormalidone, and drospirenone should be used. However, they have been associated with increased risk of venous thrombosis [65,66,67].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.2. Hormonal Contraceptives
What the sources say
- Not checked yetcites [65] Bird, 2013, Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of ethinyl-estradiol?, J. Thromb. Haemost. source
- Partly supportedcites [66] Cushman, 2004, Estrogen plus progestin and risk of venous thrombosis, JAMA sourceExperimental — accuracy not yet measured
The COMMENT section reports increased venous-thrombosis risk with estrogen plus progestin in postmenopausal women. But the Participants section identifies the studied progestin as medroxyprogesterone acetate; the paper does not establish the claimed association for cyproterone acetate, chlormalidone, or drospirenone, or address their androgenic action. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [67] Gronich, 2011, Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study, CMAJ sourceExperimental — accuracy not yet measured
The Results report increased venous-thrombosis risk with drospirenone-containing contraceptives relative to second- and third-generation contraceptives. They do not establish the same association for cyproterone acetate or chlormadinone; the Results explicitly say the chlormadinone sample was too small to analyze. The source therefore supports the risk claim for drospirenone, but not for all three named progestins. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, the most studied medication is metformin, which seems to positively influence microbiota diversity and composition [61].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.1. Insulin Sensitizers
What the sources say
- Partly supportedcites [61] Montandon, S.A., and Jornayvaz, F.R. (2017). Effects of antidiabetic drugs on gut microbiota composition. Genes, 8. sourceExperimental — accuracy not yet measured
Section 3 (Discussion) describes metformin as the most studied medication and reports increases in potentially beneficial bacteria, supporting the composition part. But Section 2.2 (Biguanides) says its effects on diversity are diet-dependent and reports decreased bacterial diversity in mice on a high-fat diet. The paper therefore does not support an unqualified positive effect on diversity. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 1 with their cited sources checked
Create a free account to see all 98 claims and to verify the 79 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, chronic low-grade inflammation is commonly observed in this population, contributing to metabolic dysregulation and an increased risk of comorbidities such as T2DM and cardiovascular disease13.”
From Cross-sectional study of the relationship between dietary inflammatory index and inflammatory hormonal and metabolic profiles in polycystic ovary syndrome (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, myoinositol might improve oocyte and embryo quality [5] by encouraging translocation of GLUT4 to the plasma membrane in order to increase glucose uptake [53] and promote aromatase activity.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperinsulinaemia, however, can contribute to certain obesity complications or related diseases, including hormonal disorders related to sex hormones and cancer (ie, mitogenic effect of insulin).98,99”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In women, hormonal dysfunction of adipose tissue and hyperinsulinaemia (which can act as a gonadotrophin) from insulin resistance constitute the main links to development of functional hyperandrogenism or polycystic ovary syndrome.98”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“As direct assays to measure free testosterone are not entirely reliable, another useful tool for the assessment of biochemical hyperandrogenism is free testosterone calculated using the formula of Vermeulen and collogues [36].”
MethodThe Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · cited 3×
“In skeletal muscle, the inhib ion of phosphoi sitide-3 kinase nd phosp orylation of i sulin recep or sub trate 1 le ds to impaired insulin signali g by altering the GLUT-4 xpression and glucose uptake [6,7].”
BackgroundInsulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The second problem is related to the various methods of measurement (fasting insulin or after glucose loading), which do not correlate with what has been found using more accurate and sophisticated laboratory methods [40].”
MethodBonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456 · cited 1×
“In clinical practice, HOMA-IR is the most common test used in research studies to measure insulin resistance, as it has been shown to closely approximate the results of clamp studies over many years [41,42].”
ResultAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“However, this latter phenotype is not included among PCOS according to the Androgen Excess Society guideline, which suggests the presence of both hyperandrogenism and ovarian dysfunction [31].”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 2×
“In particular, insulin and LH act synergistically on the theca cells, stimulating ovarian androgen production [4].”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/er.18.6.774 · Cited by 1,155
Makki, K., Froguel, P., & Wolowczuk, I. (2013) · ISRN Inflammation · doi:10.1155/2013/139239 · Cited by 1,085 · cited 1×
“Another important pro-inflammatory agent involved in the pathogenesis of PCOS is adipose tissue [18].”
BackgroundInflammatory mechanisms in the regulation of insulin resistance
Tilg, H., & Moschen, A. R. (2008) · Molecular Medicine · doi:10.2119/2007-00119.tilg · Cited by 779 · cited 1×
“It is known that adipose tissue-resident macrophages release TNF-α and IL-6, which are implicated in the induction of insulin resistance [19].”
BackgroundChronic Low Grade Inflammation in Pathogenesis of PCOS
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A. M., Smolarczyk, R., & Meczekalski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073789 · Cited by 680 · cited 3×
“The release of inflammatory markers is associated with long-term metabolic complications and high cardiovascular risk [12].”
BackgroundEstrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
Update on PCOS: consequences, challenges, and guiding treatment
Hoeger, K. M., Dokras, A., & Piltonen, T. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa839 · Cited by 610 · cited 1×
“Phenotype (D), only with polycystic ovarian morphology and oligo-anovulation, is also considered among the forms of PCOS [30].”
BackgroundEvidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Shelley, D. R., Green, G., Dobrjansky, A., & Licholai, T. (1992) · Diabetes · doi:10.2337/diab.41.10.1257 · Cited by 546 · cited 1×
“An old study argued that in PCOS, the mechanism underlying insulin resistance decreased autophosphorylation of the insulin receptor following insulin binding [5].”
BackgroundMartin, K. A., Chang, R. J., Ehrmann, D. A., Ibanez, L., Lobo, R. A., Rosenfield, R. L., Shapiro, J., Montori, V. M., & Swiglo, B. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2437 · Cited by 512
Elsenbruch, S., Hahn, S., Kowalsky, D., Öffner, A. H., Schedlowski, M., Mann, K., & Janssen, O. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030562 · Cited by 437 · cited 1×
“and metabolic aspects [51], and directly through its action on the synthesis and secretion of neurosteroids, such as allopregnanolone [52].”
BackgroundPalomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426 · cited 1×
“However, the beneficial effects of metformin are increasingly evident, especially when combined with lifestyle modifications, improving the pathogenetic mechanisms underlying PCOS, restoring ovarian function, and improving metabolic profile, especially insulin sensitivity and, unlike COCs, lipoprotein pattern [49].”
BackgroundCassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016) · Human Reproduction · doi:10.1093/humrep/dew243 · Cited by 415 · cited 1×
“have a significant reduction in insulin sensitivity compared to BMI and age-matched controls [25,39].”
BackgroundImpact of Obesity on the Risk for Polycystic Ovary Syndrome
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1834 · Cited by 401 · cited 1×
“For example, an exaggerated production of tumor necrosis factor (TNF-α) produced by monocytes as a response to hyperglycemia could exacerbate the metabolic and hormonal abnormalities of PCOS [10].”
BackgroundTremellen, K., & Pearce, K. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.04.016 · Cited by 359 · cited 3×
“The consequence could be the activation of the immune system, insulin resistance, and hyperandrogenism [8].”
BackgroundInfluentialMartin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00241 · Cited by 339 · cited 7×
“Serum free testosterone is higher than total testosterone, especially in PCOS, who commonly have reduced SHBG levels, mainly due to insulin resistance.”
BackgroundInfluentialMolecular mechanisms of insulin resistance in polycystic ovary syndrome
Diamanti-Kandarakis, E., & Papavassiliou, A. G. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.05.006 · Cited by 301 · cited 2×
“In skeletal muscle, the inhib ion of phosphoi sitide-3 kinase nd phosp orylation of i sulin recep or sub trate 1 le ds to impaired insulin signali g by altering the GLUT-4 xpression and glucose uptake [6,7].”
BackgroundSGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
Dapas, M., Lin, F. T. J., Nadkarni, G. N., Sisk, R., Legro, R. S., Urbanek, M., Hayes, M. G., & Dunaif, A. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003132 · Cited by 297 · cited 1×
“recently analyzed the heterogeneity of PCOS phenotypes by using biochemical and genotypic data from a published PCOS genome-wide association study [34].”
MethodPolycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294 · cited 2×
“Recently, advanced glycosylation end products (AGEs) and their receptors implicated in the inflammation and oxidative stress cascades have also been found to be overexpressed in PCOS women [11].”
BackgroundElkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · cited 1×
“The combination of GLP-1 RA and metformin seems to be superior to each single-agent alone, for improving not only BMI, central adiposity, and insulin resistance, but also menstrual cycles and hyperandrogenism, especially in obese PCOS patients [57,58].”
Background11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome
O’Reilly, M. W., Kempegowda, P., Jenkinson, C., Taylor, A. E., Quanson, J. L., Storbeck, K.-H., & Arlt, W. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3285 · Cited by 267
Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome
Moghetti, P., Tosi, F., Bonin, C., Di Sarra, D., Fiers, T., Kaufman, J.-M., Giagulli, V. A., Signori, C., Zambotti, F., Dall'Alda, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3908 · Cited by 262 · cited 3×
“In contrast, normo-androgenic PCOS (phenotype D) have a lower risk of metabolic disorders [25].”
BackgroundMetabolic risk in PCOS: Phenotype and adiposity impact
Moran, L. J., Norman, R. J., & Teede, H. J. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.12.003 · Cited by 245 · cited 1×
“Previous studies have associated the androgenic phenotype with more severe metabolic alterations [32,33].”
BackgroundAboeldalyl, S., James, C., Seyam, E., Ibrahim, E. M., Shawki, H. E.-D., & Amer, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052734 · Cited by 239 · cited 1×
“These observations need confirmation in larger studies directly assessing the presence of inflammation in the fat tissues of PCOS women [21].”
BackgroundDumesic, D. A., Akopians, A. L., Madrigal, V. K., Ramirez, E., Margolis, D. J., Sarma, M. K., Thomas, A. M., Grogan, T. R., Haykal, R., Schooler, T. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2586 · Cited by 222 · cited 1×
“metabolic aspects such as alterations in cholesterol and fat distribution [62], but they can also cause side effects that must be considered, especially in PCOS women with metabolic and cardiovascular risk factors [63].”
BackgroundInsulin resistance and PCOS: chicken or egg?
Moghetti, P., & Tosi, F. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01351-0 · Cited by 209 · cited 1×
“In particular, obesity, age, androgen levels, metabolism and clearance of insulin, and enzymatic degradation of the insulin–receptor complex are perhaps more valuable than insulin itself [44].”
BackgroundCorbould, A. (2007) · Journal of Endocrinology · doi:10.1677/joe.1.07070 · Cited by 184 · cited 1×
“At the level of adipose tissue, testosterone acts by decreasing protein kinase C (PKC) phosphorylation [27], whereas on skeletal muscle, it acts by increasing the phosphorylation of the mammalian target of rapamycin (mTOR) and ribosomal kinase S6 (S6K), leading to increased serine phosphorylation of IRS-1 [28].”
BackgroundShorakae, S., Ranasinha, S., Abell, S., Lambert, G., Lambert, E., de Courten, B., & Teede, H. (2018) · Clinical Endocrinology · doi:10.1111/cen.13808 · Cited by 176 · cited 1×
“Hyperandrogenism leads to aberrant adipose tissue functions in PCOS [20].”
BackgroundOVARIAN AND ADRENAL FUNCTION IN POLYCYSTIC OVARY SYNDROME
Rosenfield, R. L. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70070-0 · Cited by 163 · cited 1×
“Alterations in adrenal steroidogenesis due to CYP17α1 hyperactivation [22] could also contribute to the hyperandrogenism of PCOS [23].”
BackgroundTosi, F., Bonora, E., & Moghetti, P. (2017) · Human Reproduction · doi:10.1093/humrep/dex308 · Cited by 163 · cited 1×
“In actual fact, they are more valuable in ruling in rather than ruling out insulin resistance in PCOS, especially among normal weight women [43].”
BackgroundTsilchorozidou, T., Honour, J. W., & Conway, G. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030240 · Cited by 155 · cited 2×
“These side effects are also accentuated by the effect of estrogen to increase cortisol binding globulin (CBG) and stimulate ACTH synthesis to maintain adequate free cortisol [24].”
BackgroundInositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154 · cited 2×
“On the contrary, the supplementation of DCI alone may worsen the insulin-mediated androgen synthesis and fertility in PCOS women [53].”
BackgroundResultGronich, N., Lavi, I., & Rennert, G. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110463 · Cited by 135
Effects of Antidiabetic Drugs on Gut Microbiota Composition
Montandon, S., & Jornayvaz, F. (2017) · Genes · doi:10.3390/genes8100250 · Cited by 135
The intersection of metformin and inflammation
Bharath, L. P., & Nikolajczyk, B. S. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00604.2020 · Cited by 134 · cited 1×
“This mechanism can regulate T-cell balance as reported in mice, where metformin reduces CD4 +/IL-17 + (TH17) and increases CD4 +/Foxp3 + (TREG) [50].”
BackgroundCardiovascular disease risk in women with PCOS
Dokras, A. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.009 · Cited by 132 · cited 1×
“metabolic aspects such as alterations in cholesterol and fat distribution [62], but they can also cause side effects that must be considered, especially in PCOS women with metabolic and cardiovascular risk factors [63].”
BackgroundCalò, L. A., Zaghetto, F., Pagnin, E., Davis, P. A., de Mozzi, P., Sartorato, P., Martire, G., Fiore, C., & Armanini, D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031545 · Cited by 122 · cited 1×
“We characterized aldosterone receptors in human mononuclear leukocytes [15], and subsequent studies confirmed that the incubation of lymphocytes with excess aldosterone increased the protein expression of PAI 1 and p22phox, two markers of inflammation [16].”
BackgroundSelf-citationSerum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome
Cascella, T., Palomba, S., Tauchmanovà, L., Manguso, F., Di Biase, S., Labella, D., Giallauria, F., Vigorito, C., Colao, A., Lombardi, G., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0399 · Cited by 120 · cited 3×
“In addition, spironolactone is a mineralocorticoid receptor antagonist and its use as monotherapy or in addition to COCs has been proposed to reduce side effects related to RAAS activation in PCOS, particularly the pro-inflammatory status, some metabolic alterations, and hypertension [74].”
BackgroundPolycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment
Parker, J., O’Brien, C., Hawrelak, J., & Gersh, F. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031336 · Cited by 114 · cited 2×
“In evolutionary terms, women with a PCOS metabolic phenotype would have increased survival chances during times of environmental or physiological need for altered energy metabolism, but would be more vulnerable to the pathological effects of insulin resistance when exposed to modern lifestyle factors [38].”
BackgroundPolycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment
parker, J., O'Brien, C., Hawrelak, J., & Gersh, F. (2021) · doi:10.20944/preprints202112.0088.v1 · Cited by 113
Yang, R., Yang, S., Li, R., Liu, P., Qiao, J., & Zhang, Y. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0203-8 · Cited by 106 · cited 1×
“Previous studies have associated the androgenic phenotype with more severe metabolic alterations [32,33].”
BackgroundInositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102 · cited 1×
“Subsequent studies have demonstrated that the combination MYO and DCI in a 40:1 ratio is the most similar to the plasma ratio reported in healthy women and is the most effective at improving ovarian function and metabolic profile in PCOS patients [55].”
BackgroundDonà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0840 · Cited by 89 · cited 1×
“In particular, several studies have confirmed the role of MYO and DCI as insulin sensitizers, improving both metabolic and oxidative imbalance [54].”
BackgroundSelf-citationUpdate on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82 · cited 1×
“In the last years, several studies demonstrated safety and efficacy of exenatide and liraglutide use, alone or in combinations with metformin, in PCOS women [56].”
BackgroundMoghetti, P., Castello, R., Negri, C., Tosi, F., Magnani, C. M., Fontanarosa, M. C., Armanini, D., & Muggeo, M. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57785-1 · Cited by 81 · cited 1×
“Flutamide has an excellent androgen receptor blocking action, but, in some cases, can give major effects, including fulminant hepatitis [79,80].”
BackgroundSelf-citationEndocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective
Dumesic, D. A., Abbott, D. H., Sanchita, S., & Chazenbalk, G. D. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.013 · Cited by 76 · cited 1×
“Guidelines generally focus on the symptoms of PCOS, but remain more elusive regarding the mechanisms leading to the disease, such as insulin resistance, a very common condition in PCOS, which is worsened by hyperandrogenism-related adipose tissue accumulation [3] and is involved in both the pathogenesis and the progre…”
BackgroundTreatment of polycystic ovary syndrome with spironolactone plus licorice
Armanini, D., Castello, R., Scaroni, C. M., Bonanni, G., Faccini, G., Pellati, D., Bertoldo, A., Fiore, C., & Moghetti, P. (2006) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2006.10.013 · Cited by 75 · cited 1×
“The addition of pure licorice has been proposed to regulate the hyperkalemic and hypotensive effect of spironolactone in normotensive women, and to enhance the antiandrogenic effects by partially blocking 17β-hydroxystreroid dehydrogenase in the adrenals and ovaries [76,77].”
BackgroundSelf-citationLicorice: From Pseudohyperaldosteronism to Therapeutic Uses
Sabbadin, C., Bordin, L., Donà, G., Manso, J., Avruscio, G., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00484 · Cited by 72
Self-citationPalomba, S., Falbo, A., Chiossi, G., Muscogiuri, G., Fornaciari, E., Orio, F., Tolino, A., Colao, A., La Sala, G. B., & Zullo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.005 · Cited by 69 · cited 6×
“Previous studies found that PCOS women have a significant reduction in insulin sensitivity compared to BMI and age-matched controls [25,39].”
BackgroundInfluentialMoghetti, P., Castello, R., Magnani, C. M., Tosi, F., Negri, C., Armanini, D., Bellotti, G., & Muggeo, M. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.4.7962284 · Cited by 69
Self-citationTeede, H. J., Meyer, C., Hutchison, S. K., Zoungas, S., McGrath, B. P., & Moran, L. J. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.034 · Cited by 68 · cited 1×
“The excess estrogenic component may worsen insulin resistance, but its effect is modulated by the associated progestin [64].”
BackgroundAllemand, M. C., Irving, B. A., Asmann, Y. W., Klaus, K. A., Tatpati, L., Coddington, C. C., & Nair, K. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004274 · Cited by 65 · cited 1×
“At the level of adipose tissue, testosterone acts by decreasing protein kinase C (PKC) phosphorylation [27], whereas on skeletal muscle, it acts by increasing the phosphorylation of the mammalian target of rapamycin (mTOR) and ribosomal kinase S6 (S6K), leading to increased serine phosphorylation of IRS-1 [28].”
BackgroundEstrogen and progesterone therapy and meningiomas
Hage, M., Plesa, O., Lemaire, I., & Raffin Sanson, M. L. (2022) · Endocrinology · doi:10.1210/endocr/bqab259 · Cited by 63
Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature
Javier, B., Magdalena, B., Roberto, S., Ricardo, L., Rodrigo, Z., Jaime, P., Erwin, B., & Luis, C. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31595-9 · Cited by 62 · cited 1×
“Flutamide has an excellent androgen receptor blocking action, but, in some cases, can give major effects, including fulminant hepatitis [79,80].”
BackgroundControversies in the diagnosis of polycystic ovary syndrome
Rao, P., & Bhide, P. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120913032 · Cited by 58 · cited 2×
“Testosterone is usually measured in PCOS, however, the common direct assays, such as RIA, ELISA, and CLIA, show poor sensitivity, mainly because they were designed to measure testosterone in males [29].”
BackgroundJENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56 · cited 1×
“The combination of GLP-1 RA and metformin seems to be superior to each single-agent alone, for improving not only BMI, central adiposity, and insulin resistance, but also menstrual cycles and hyperandrogenism, especially in obese PCOS patients [57,58].”
BackgroundSpironolactone in the treatment of polycystic ovary syndrome
Armanini, D., Andrisani, A., Bordin, L., & Sabbadin, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215430 · Cited by 53 · cited 3×
“The effect on hair loss occurs over a longer period of time because the half-life of hair is very long and therefore at least 5–6 months of therapy are required to see a subjective effect [26].”
BackgroundSelf-citationMetabolic impact of combined hormonal contraceptives containing estradiol
Grandi, G., Napolitano, A., & Cagnacci, A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1190832 · Cited by 50 · cited 1×
“The recent development of two COCs containing natural estrogen (17-estradiol and 17-estradiol valerate) could be a valid therapeutic alternative in PCOS, showing a more favorable effect on metabolic profile, RAAS induction, and hemostatic balance compared with ethinyl estradiol [70,71].”
BackgroundPharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism
Bastianelli, C., Farris, M., Rosato, E., Brosens, I., & Benagiano, G. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1271708 · Cited by 50 · cited 1×
“The recent development of two COCs containing natural estrogen (17-estradiol and 17-estradiol valerate) could be a valid therapeutic alternative in PCOS, showing a more favorable effect on metabolic profile, RAAS induction, and hemostatic balance compared with ethinyl estradiol [70,71].”
BackgroundArmanini, D., Bordin, L., Donà, G., Sabbadin, C., Bakdounes, L., Ragazzi, E., Giorgino, F. L., & Fiore, C. (2012) · Steroids · doi:10.1016/j.steroids.2012.02.010 · Cited by 45 · cited 7×
“It has been shown that aldosterone and, in particular, the aldosterone/renin ratio are often increased in PCOS, and this accentuates the underlying inflammatory state and might be involved in the development of some metabolic and cardiovascular disorders [14].”
BackgroundInfluentialSelf-citationSo, A., Sakaguchi, K., Okada, Y., Morita, Y., Yamada, T., Miura, H., Otowa-Suematsu, N., Nakamura, T., Komada, H., Hirota, Y., et al. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0445 · Cited by 45 · cited 1×
“In clinical practice, HOMA-IR is the most common test used in research studies to measure insulin resistance, as it has been shown to closely approximate the results of clamp studies over many years [41,42].”
ResultParker, J., O'Brien, C., & Hawrelak, J. (2022) · Obstetrics & Gynecology Science · doi:10.5468/ogs.21185 · Cited by 42 · cited 1×
“A recent revision of 31 studies published in t e last 10 years reported reduc d alpha diversity and dysbiosis in women with PCOS [9].”
BackgroundAldosterone receptor blockers spironolactone and canrenone: Two multivalent drugs
Armanini, D., Sabbadin, C., Donà, G., Clari, G., & Bordin, L. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.896901 · Cited by 41 · cited 1×
“In addition, spironolactone is a mineralocorticoid receptor antagonist and its use as monotherapy or in addition to COCs has been proposed to reduce side effects related to RAAS activation in PCOS, particularly the pro-inflammatory status, some metabolic alterations, and hypertension [74].”
BackgroundSelf-citationThe endocrine effects of spironolactone used as an antiandrogen
Young, R. L., Goldzieher, J. W., & Elkind-Hirsch, K. (1987) · Fertility and Sterility · doi:10.1016/s0015-0282(16)59346-7 · Cited by 38 · cited 1×
“Spironolactone has several antiandrogen effects such as androgen receptor blockade, aromatase stimulation, and direct effect of partial blockade of androgen synthesis, not only in the gonads but also in the adrenals through a direct effect on ovarian and adrenal androgen synthesis [26,73].”
BackgroundPharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36 · cited 4×
“Recent studies have also evaluated the effects of other insulin sensitizer drugs, wellknown and prescribed for diabetes mellitus type 2, such as incretin mimetics and sodium– glucose co-transporter type 2 inhibitors (SGLT2-i), which could be probably more effective on certain comorbidities, such as obesity and cardiov…”
BackgroundInfluentialSelf-citationMarinkovic-Radosevic, J., Cigrovski Berkovic, M., Kruezi, E., Bilic-Curcic, I., & Mrzljak, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.932 · Cited by 35 · cited 1×
“Recent studies have shown that the use of SGLT2-i improves anthropometric parameters and body composition in PCOS patients, but the effects on ovulation, menstrual frequency, and hyperandrogenism have not been assessed yet [60].”
BackgroundSpironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI
Sabbadin, C., Andrisani, A., Zermiani, M., Donà, G., Bordin, L., Ragazzi, E., Boscaro, M., Ambrosini, G., & Armanini, D. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0466-0 · Cited by 33 · cited 1×
“The adverse effects are intermenstrual bleedings, related to a selective progesterone receptor modulator effect of spironolactone [75].”
BackgroundSelf-citationMetabolic health during a randomized controlled lifestyle intervention in women with PCOS
Dietz de Loos, A., Jiskoot, G., Beerthuizen, A., Busschbach, J., & Laven, J. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0669 · Cited by 33 · cited 1×
“Physical activity and diet represent the first therapeutic approach for PCOS patients, improving weight, insulin resistance, hyperandrogenism, and the inflammatory state often present in PCOS [47].”
BackgroundAdrenal involvement in polycystic ovary syndrome
Gonzalez, F. (1997) · Seminars in Reproductive Medicine · doi:10.1055/s-2007-1016296 · Cited by 30 · cited 1×
“It is important to keep in mind that previous studies have also demonstrated an adrenal contribution to hyperandrogenism in PCOS [69].”
BackgroundYıldız, B. O., Woods, K. S., Stanczyk, F. Z., Bartolucci, A., & Azziz, R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0934 · Cited by 30 · cited 1×
“Alterations in adrenal steroidogenesis due to CYP17α1 hyperactivation [22] could also contribute to the hyperandrogenism of PCOS [23].”
BackgroundGenazzani, A. D., Chierchia, E., Rattighieri, E., Santagni, S., Casarosa, E., Luisi, M., & Genazzani, A. R. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.500818 · Cited by 26 · cited 1×
“and metabolic aspects [51], and directly through its action on the synthesis and secretion of neurosteroids, such as allopregnanolone [52].”
BackgroundBird, S. T., Delaney, J. A. C., Etminan, M., Brophy, J. M., & Hartzema, A. G. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12224 · Cited by 22
Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy
Sabbadin, C., Andrisani, A., Ambrosini, G., Bordin, L., Donà, G., Manso, J., Ceccato, F., Scaroni, C., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00575 · Cited by 22 · cited 4×
“An underestimated factor in the diagnosis and treatment of PCOS is aldosterone [13].”
BackgroundInfluentialSelf-citationArmanini, D., Strasser, T., & Weber, P. C. (1985) · PubMed · Cited by 15
Self-citation
Cited by
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
“98 The clinical symptoms of these disorders are menstruation disturbances (due to impaired ovulation), hirsutism, acne, and impaired fertility.”
InfluentialZhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
“Studies suggest that a more complex evaluation of the decrease in insulin sensitivity as a continuous variable is required in clinical practice [10].”
BackgroundGreff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“In addition, myoinositol might improve oocyte and embryo quality [5] by encouraging translocation of GLUT4 to the plasma membrane in order to increase glucose uptake [53] and promote aromatase activity.”
BackgroundXiang, Y., Wang, H., Ding, H., Xu, T., Liu, X., Huang, Z., Wu, H., & Ge, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111141 · Cited by 142
Zhang, C.-H., Liu, X., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216247 · Cited by 146
Metadata
- Authors
- Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Armanini, Decio
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-08
- Volume
- 23
- Issue
- 8
- Pages
- 4110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9030414
- OpenAlex
- W4224247712
- Semantic Scholar
- 6ba01eafb58b7f3a48fb9c3789a3b5c603a63b92
- Cited by
- 324
- References
- 85
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 82 · 2023: 58 · 2022: 13
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, insulin resistance, inflammation, hyperandrogenism, PCOS pathogenesis, PCOS diagnosis, PCOS treatment, androgen receptor antagonists, metabolic disorders, oligoanovulation, PCOS phenotypes
- MeSH terms
- Female, Humans, Inflammation, Insulin Resistance, Metabolic Diseases, Polycystic Ovary Syndrome, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
